Hematological anlotinib monotherapy or combination treatment-related AEs were decreased neutrophil count (n=15, 34.9%), decreased white blood count (n=15, 34.9%), anemia (n=11, 25.6%), decreased platelet (n=5, 11.6%), increased ALT/AST (n=10, 23.3%) and hyperbilirubinemia (n=4, 9.3%). The gene discussed is GPT; the disease is anemia.